PCOS Phenotypes: A Diagnostic Overview

From Criteria to Phenotypes

The term phenotype refers to the observable characteristics of an individual. In the context of PCOS, a phenotype is the specific combination of the three Rotterdam criteria that a patient exhibits:

1. Hyperandrogenism (HA): Clinical signs (like hirsutism) or biochemical evidence (high androgen levels).
2. Ovulatory Dysfunction (OD): Irregular, infrequent, or absent menstrual cycles.
3. Polycystic Ovarian Morphology (PCOM): The characteristic appearance of the ovaries on ultrasound.

Because the Rotterdam criteria require any two of these three features, four possible combinations emerge. These combinations were formally classified into four main phenotypes (A, B, C, and D) by an NIH consensus panel in 2012, providing a standardized way to talk about the different presentations of PCOS.

To begin, let's get a clear definition of these four phenotypes.

The Four Phenotypes of PCOS

As you just read, the four phenotypes are defined by which of the three Rotterdam criteria are present. Here is a summary:

This image provides a helpful visual breakdown of the phenotypes.

Let's look at each one more closely:

• Phenotypes A and B are considered "classic" forms of PCOS because they both meet the original, stricter 1990 NIH criteria (HA + OD). The only difference is the presence or absence of PCOM on ultrasound.
• Phenotype C represents "ovulatory PCOS." These women have signs of androgen excess and PCOM but experience regular menstrual cycles. This phenotype is only recognized under the Rotterdam and AE-PCOS criteria.
• Phenotype D is the "non-hyperandrogenic" form. These women have irregular cycles and PCOM but normal androgen levels. This is the most controversial phenotype, as it is only diagnosed using the Rotterdam criteria and is excluded by both the NIH and AE-PCOS criteria, which consider hyperandrogenism essential to the syndrome.

Clinical and Metabolic Differences Among Phenotypes

Defining these groups is only useful if they differ in meaningful ways. Research consistently shows that they do, particularly regarding metabolic risk and severity.

Let's return to the study by Sachdeva et al. to see a direct comparison of the clinical and metabolic profiles of women with these different phenotypes.

As the study highlights, there is a clear gradient of severity across the phenotypes:

• Phenotype A (Full PCOS) is consistently found to be the most common and most severe phenotype. Individuals in this group tend to have a higher BMI, more significant clinical and biochemical hyperandrogenism, worse insulin resistance, and more abnormal cholesterol levels (dyslipidemia). This places them at the highest risk for long-term metabolic complications like type 2 diabetes and cardiovascular disease.
• Phenotype D (Non-Hyperandrogenic) represents the mildest metabolic profile. These individuals generally have the lowest risk for insulin resistance and its associated complications among the four groups.
• Phenotypes B (Classic, Non-PCO) and C (Ovulatory) typically fall in the middle, presenting with an intermediate metabolic risk profile that is more severe than Phenotype D but less so than Phenotype A.

It is important to note that while Phenotype A is often the most common, the prevalence of each phenotype can vary significantly across different ethnic populations and geographical regions, as discussed in the paper "Comparison of the various diagnostic criteria used in polycystic ovary syndrome" (LINK). This highlights the complex interplay of genetic and environmental factors in shaping how PCOS manifests.

Why Phenotyping Matters

Classifying a patient into a specific phenotype is more than an academic exercise. It has significant clinical implications:

1. Prognosis and Risk Stratification: It allows for a more accurate prediction of a patient's long-term health risks. A woman with Phenotype A can be counseled that she has a higher intrinsic risk for metabolic syndrome and needs more diligent screening and lifestyle management compared to a woman with Phenotype D.
2. Guiding Treatment: The phenotype can influence treatment response. For example, the Sachdeva et al. study found that women with Phenotype A were more likely to be resistant to the ovulation-induction drug clomiphene.
3. Improving Research: By grouping patients into more uniform phenotypes, researchers can produce clearer and more reliable data on the causes, consequences, and best treatments for the different facets of PCOS.

Conclusion

In this lesson, we have moved beyond a single, uniform diagnosis of PCOS to appreciate its heterogeneity. You can now describe the four main phenotypes that arise from the Rotterdam diagnostic criteria and understand how they differ.

Key Takeaways:

• PCOS is not a single entity but a syndrome with at least four distinct presentations, or phenotypes, based on the combination of hyperandrogenism (HA), ovulatory dysfunction (OD), and polycystic ovarian morphology (PCOM).
• Phenotype A (HA + OD + PCOM) is the "full" or classic severe form, and is typically the most common and carries the highest metabolic risk.
• Phenotype D (OD + PCOM) is the "non-hyperandrogenic" form, which has the mildest metabolic profile and is only diagnosed under the Rotterdam criteria.
• Identifying a patient's phenotype is clinically important for predicting long-term health risks, counseling patients, and potentially tailoring treatment strategies.

Preview of the Next Lesson:
Before we can confidently assign a PCOS diagnosis and phenotype, we must be certain that the patient's symptoms are not caused by another medical condition. In our next lesson, we will address this critical step: Explain the importance of excluding other medical conditions that mimic PCOS.